Court upholds patents on Pfizer cancer drug Sutent
Thursday, January 14, 2016
A federal appeals court has upheld the validity of Pfizer Inc's patents on its cancer drug Sutent, blocking Mylan Pharmaceuticals Inc from launching a generic version of the drug.
The ruling, handed down Wednesday by the Federal U.S. Circuit Court of Appeals, affirmed a lower court decision. Circuit Judges Timothy Dyk, Evan Wallach and Todd Hughes concurred in the decision, but did not provide a written opinion.
reuters.com
